Resumen
Histone deacetylase inhibitors (HDACIs) represent a relatively new drug class with potent regulatory effects on the epigenetics in cancer, ranging from apoptosis induction and cancer cell death to cell cycle arrest. In spite of the fact that HDACIs have, so far, received approval for the treatment of mainly hematologic malignancies, there are numerous preclinical, as well as, clinical trials in the setting of (triple negative) breast cancer with very promising results. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. A total of 138 breast cancer specimens were examined immunohistochemically. This current study demonstrated that increased HDAC-2 expression correlates with significant clinicopathological parameters of triple negative breast cancer patients, such as survival, recurrence, and disease stage.